Scantox appoints Morten Fjordholt as Sr. Business Development Director - Scantox

Blog & News

  1. Home
  2. Posts
  3. Scantox appoints Morten Fjordholt as Sr. Business Development Director

Scantox appoints Morten Fjordholt as Sr. Business Development Director

Nov 8, 2023

November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships with current and prospective clients.

Morten Fjordholt is an experienced Molecular Biologist and pharmaceutical Toxicologist with over two decades of experience in the life science and drug development industry. Morten has made significant contributions to our industry. Over the past eight years, he played a crucial role in expanding the Scandinavian market share for companies like Huntingdon Life Science, Envigo, Covance, and Labcorp. Beyond his professional success, Morten is actively involved in the field. He is a board member of the Danish Toxicology & Pharmacology Society and a full accredited member of both the Society of Toxicology (SOT) and the American College of Toxicology (ACT). Additionally, he started a successful and growing series of symposia and courses on drug development.

“I am thrilled to join Scantox at this pivotal moment in the company’s growth and I see this as a remarkable opportunity to work with a team of highly talented individuals who are actively driving progress in the development of innovative medicines for patients. I look forward to contributing my expertise to further advance Scantox’s position as a leader in the field,” said Morten Fjordholt.

We are delighted to add a top talent like Morten to our growing team and believe his preclinical knowledge and experience in the Pharmaceutical, biotech and CRO industry bring significant value to Scantox Group and all its customers,” said Andy Brown, Chief Commercial Officer of Scantox Group.

  

For further information, please contact: 

Andy Brown, CCO of Scantox, abr@scantox.com 

About Scantox Group  

Scantox is the leading Nordic preclinical GLP-accredited Contract Research Organization, focused on pharmacology and regulatory toxicology. We are headquartered in Denmark, in the same location as where the company was originally founded in 1977. In addition, Scantox has several subsidiaries in Sweden.

Scantox is specialized in preclinical contract research services. Our scientific work enables pharmaceutical and biotechnology companies to progress drug development projects, based on solid high-quality data. Core competencies within the Scantox Group include Explorative and efficacy studies, PK-studies, general toxicology studies including Juvenile & EFD, local tolerance studies, wound healing studies and vaccines. GLP compliant. Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into studies in early discovery as well as preclinical tests that overlap into phases 1 and 2. As one of the most experienced preclinical service providers, our in-vivo work is backed by decades of experience. This makes Scantox a highly trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a globally recognized leader for our expertise and long experience with the Göttingen Minipig. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards. Scantox is today owned by Impilo, the leading Nordic healthcare investment company.